Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Expression of coxsackievirus and adenovirus receptor (CAR)-Fc fusion protein in Pichia pastoris and characterization of its anti-coxsackievirus activity.

Zhang K, Yu H, Xie W, Xu Z, Zhou S, Huang C, Sheng H, He X, Xiong J, Qian G.

J Biotechnol. 2013 Apr 15;164(4):461-8. doi: 10.1016/j.jbiotec.2013.01.015. Epub 2013 Jan 30.

PMID:
23376619
2.

Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.

Yanagawa B, Spiller OB, Proctor DG, Choy J, Luo H, Zhang HM, Suarez A, Yang D, McManus BM.

J Infect Dis. 2004 Apr 15;189(8):1431-9. Epub 2004 Apr 5.

PMID:
15073680
3.

Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virus.

Pinkert S, Dieringer B, Diedrich S, Zeichhardt H, Kurreck J, Fechner H.

Antiviral Res. 2016 Dec;136:1-8. doi: 10.1016/j.antiviral.2016.10.010. Epub 2016 Oct 20.

PMID:
27773751
4.

Interspecies differences in virus uptake versus cardiac function of the coxsackievirus and adenovirus receptor.

Freiberg F, Sauter M, Pinkert S, Govindarajan T, Kaldrack J, Thakkar M, Fechner H, Klingel K, Gotthardt M.

J Virol. 2014 Jul;88(13):7345-56. doi: 10.1128/JVI.00104-14. Epub 2014 Apr 16.

5.

Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells.

Funke C, Farr M, Werner B, Dittmann S, Uberla K, Piper C, Niehaus K, Horstkotte D.

J Gen Virol. 2010 Aug;91(Pt 8):1959-70. doi: 10.1099/vir.0.020065-0. Epub 2010 Apr 14.

PMID:
20392896
6.

Treatment of coxsackievirus-B3-infected BALB/c mice with the soluble coxsackie adenovirus receptor CAR4/7 aggravates cardiac injury.

Dörner A, Grunert HP, Lindig V, Chandrasekharan K, Fechner H, Knowlton KU, Isik A, Pauschinger M, Zeichhardt H, Schultheiss HP.

J Mol Med (Berl). 2006 Oct;84(10):842-51. Epub 2006 Aug 5.

PMID:
16924471
7.

Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis.

Lim BK, Choi JH, Nam JH, Gil CO, Shin JO, Yun SH, Kim DK, Jeon ES.

Cardiovasc Res. 2006 Aug 1;71(3):517-26. Epub 2006 May 16.

PMID:
16806133
8.

Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3.

Werk D, Pinkert S, Heim A, Zeichhardt H, Grunert HP, Poller W, Erdmann VA, Fechner H, Kurreck J.

Antiviral Res. 2009 Sep;83(3):298-306. doi: 10.1016/j.antiviral.2009.07.002. Epub 2009 Jul 8.

PMID:
19591879
9.

Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.

Stein EA, Pinkert S, Becher PM, Geisler A, Zeichhardt H, Klopfleisch R, Poller W, Tschöpe C, Lassner D, Fechner H, Kurreck J.

J Infect Dis. 2015 Feb 15;211(4):613-22. doi: 10.1093/infdis/jiu504. Epub 2014 Sep 5.

PMID:
25193982
10.

Expression, purification and characterization of a human single-chain Fv antibody fragment fused with the Fc of an IgG1 targeting a rabies antigen in Pichia pastoris.

Wang DD, Su MM, Sun Y, Huang SL, Wang J, Yan WQ.

Protein Expr Purif. 2012 Nov;86(1):75-81. doi: 10.1016/j.pep.2012.08.015. Epub 2012 Sep 11.

PMID:
22982755
11.

Generation of a fusion protein of the extracellular domain of BR3 with the Fc fragment of human IgG1 (sBR3-Fc) in Pichia pastoris as an antagonist for BLyS.

Cao P, Zhang S, Fang Z, Huang H, Bai P, Zhang Q, Luo C.

Appl Microbiol Biotechnol. 2008 Feb;78(2):275-82. doi: 10.1007/s00253-007-1299-8. Epub 2008 Jan 10.

PMID:
18189138
12.

Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells.

Werner B, Dittmann S, Funke C, Überla K, Piper C, Niehaus K, Horstkotte D, Farr M.

Inflamm Res. 2014 Apr;63(4):267-76. doi: 10.1007/s00011-013-0695-z. Epub 2013 Dec 8.

PMID:
24316867
13.
14.
15.

[Construction and expression of a fusion protein containing extracellular domain of human Jagged1 and Fc fragment of human IgG1 in Pichia Pastoris].

Li GH, Kang ZJ, Huang SY, He F, Xu H, Zhang L, Wu YL, Niu XL, Ma CS, Han H, Liang YM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Aug;16(4):910-4. Chinese.

PMID:
18718088
16.

Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection.

Zautner AE, Körner U, Henke A, Badorff C, Schmidtke M.

J Virol. 2003 Sep;77(18):10071-7.

17.

Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes.

Jarasch-Althof N, Wiesener N, Schmidtke M, Wutzler P, Henke A.

Viral Immunol. 2010 Aug;23(4):369-76. doi: 10.1089/vim.2010.0018.

PMID:
20712481
18.

Expression of single-chain Fv-Fc fusions in Pichia pastoris.

Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD.

J Immunol Methods. 2001 May 1;251(1-2):123-35.

PMID:
11292488
19.

Activation of STAT1 transcription factor precedes up-regulation of coxsackievirus-adenovirus receptor during viral myocarditis.

Ruppert V, Meyer T, Pankuweit S, Jonsdottir T, Maisch B.

Cardiovasc Pathol. 2008 Mar-Apr;17(2):81-92. doi: 10.1016/j.carpath.2007.07.004. Epub 2007 Sep 14.

PMID:
18329552
20.

Short hairpin RNA targeting 2B gene of coxsackievirus B3 exhibits potential antiviral effects both in vitro and in vivo.

Yao H, Zhang Y, He F, Wang C, Xiao Z, Zou J, Wang F, Liu Z.

BMC Infect Dis. 2012 Aug 6;12:177. doi: 10.1186/1471-2334-12-177.

Supplemental Content

Support Center